Hester Biosciences has released its consolidated financial results for the quarter and year ending March 31, 2026.
The company has shown significant growth in both total income and net profit, reflecting its robust performance over the past year.
For the March 2026 quarter, Hester Biosciences reported a total income of ₹97.08 crore, marking a 29.5% increase compared to ₹74.98 crore in the same quarter last year.
This also represents a 24.3% rise from ₹78.08 crore in the December 2025 quarter.
The net profit for the March 2026 quarter surged by 974.7% to ₹16.55 crore, up from ₹1.54 crore a year ago, and increased by 77.8% from ₹9.31 crore in the December 2025 quarter.
For the full financial year 2025-26, Hester Biosciences' total income rose by 8.7% to ₹342.28 crore, compared to ₹315.03 crore in the previous year.
The net profit for the year almost doubled, increasing by 99.4% to ₹57.48 crore from ₹28.83 crore in the prior year.
Read More: United Spirits Share Price in Focus After Q4 FY26 Earnings Results: Net Profit up 28% YoY!
The company has recommended a dividend of ₹11 per equity share of ₹10 each, equating to 110% for the financial year 2025-26.
This recommendation is subject to approval at the upcoming Annual General Meeting.
Additionally, Ms. Priya Gandhi has been re-appointed as Executive Director for a period of 3 years starting October 28, 2026, pending member approval.
As of May 15, 2026, at 11:59 AM, Hester Biosciences share price on NSE was trading at ₹1,967.70 up by 13.07% from the previous closing price.
Hester Biosciences has demonstrated strong financial performance for the quarter and year ending March 31, 2026. With significant increases in both income and profit, the company continues to show positive growth trends.
Track the stock market in Hindi. Visit Angel One News for the latest market trends, insights, and share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 15, 2026, 1:09 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
